

1/14




FIG. 1

TI13-027: Combination of Anti-PD-L1/TGFβ Trap with 5-FU and Oxaliplatin Therapy in MC38 Tumor Model in C57BL/6 Wild Type Mice

Group and Treatment (N=10 mice/group):

Group	Group/Treatment	Dose	Route	Schedule
1	Saline	0.2 ml/mouse	i.v.	day 0, 14
	Isotype Control	400 µg/mouse	i.v.	day 3, 6, 8
2	Anti-PD-L1/TGFβ Trap	492 µg/mouse	i.v.	days 3, 6, 8
3	Oxaliplatin	5 mg/kg	i.p.	day 0, 14
	5-FU	60 mg/kg	i.v.	day 0, 14
4	Oxaliplatin	5 mg/kg	i.p.	day 0, 14
	5-FU	60 mg/kg	i.v.	day 0, 14
	Anti-PD-L1/TGFβ Trap	492 µg/mouse	i.v.	days 3, 6, 8




FIG. 2

TH14-012: Combination of Anti-PD-L1/TGFβ Trap with 5-FU and Oxaliplatin Therapy in MC38 Tumor Model in B Cell Deficient Mice

Group and Treatment (N=10 mice/group):

Group	Group/Treatment	Dose	Route	Schedule
1	Saline	0.2 ml/mouse	i.v.	day 0
	Isotype Control	400 µg/mouse	i.v.	day 3, 6, 9, 12, 17
2	Anti-PD-L1/TGFβ Trap	492 µg/mouse	i.v.	days 3, 6, 9, 12, 17
3	Oxaliplatin	5 mg/kg	i.p.	day 0
	5-FU	60 mg/kg	i.v.	day 0
4	Oxaliplatin	5 mg/kg	i.p.	day 0
	5-FU	60 mg/kg	i.v.	day 0
	Anti-PD-L1/TGFβ Trap	492 µg/mouse	i.v.	days 3, 6, 9, 12, 17





FIG. 3



5/14




FIG. 4C






FIG. 4D



8/14




FIG. 5C




FIG. 5D




FIG. 6C




FIG. 6B




FIG. 6A




FIG. 7C




FIG. 7B




FIG. 7A




FIG. 8A

FIG. 8B




FIG. 8D

FIG. 8C




FIG. 9A




FIG. 9B

FIG. 9C